Adding durvalumab to perioperative FLOT improves gastric cancer outcomes



Summary

Adding the immunotherapy drug durvalumab to the standard perioperative chemotherapy regimen FLOT significantly improves outcomes for patients with resectable gastric or gastroesophageal junction cancer. The Phase III clinical trial demonstrated a statistically significant and clinically meaningful improvement in pathological complete response (pCR) rates and event-free survival (EFS). Durvalumab combined with FLOT represents a new standard of care, offering a more effective treatment approach and a better chance for long-term survival for these patients. These findings have the potential to change clinical practice and improve patient outcomes worldwide.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!